ABSTRACT
Title
Polymorphism gene apolipoprotein E in migraine and cardiovascular disease.
Authors
V. Pizza (1), A. Agresta (1), A. Bisogno (2), A. Capasso (2)
1) Neurophysiopatology and 2) Department of Pharmaceutical and Biomedical Sciences, University of Salerno, Italy.
1) Neurophysiopatology and 2) Department of Pharmaceutical and Biomedical Sciences, University of Salerno, Italy.
Abstract
Nitric oxide plays an important role in the pathogenesis of migraine. Studies suggest that the expression of molecules involved in the pathogenesis of headache ( i.e., nitric oxide-interleukin) is influenced by apolipoprotein E (APOE) and is gene specific. Hence, we hypothesized that APOE polymorphism may be associated with migraine.
Our study analysed the incidence of genetic polymorphism Apoliporotein E in a sample of migraineurs and a control group of the patients with ischemic cardiopaty.
In this study 100 consecutive patients aged 18-64 years (mean age 33.7 years), suffering from migraine [1] (78 migraine without aura, 22 migraine with aura, ICHD-II criteria ) and 90 patients aged 36-74 years (mean age 46.5 years), with ischemic cardiopathy [2] were studied with Polymerase Chain Reaction (PCR) for genetic polymorphism Apoliporotein E.
ApoE: 71 patients (71%) [1] and 63 (70%) [2] had an E3/E3 genotype; 15 (15%) [1] and 14 (15,5%) [2] had a E3/E4 genotype; 6 (6%) [1] and 9 (10%) [2] had a E2/E3 genotype; 2 (2%) [1] and 4 (4.4%) [2] had a E4/E4 genotype; 3 (3%) [1] and 0 [2] had a E2/E4 genotype; 0 [1] and 0 [2] had a E2/E2 genotype.
Our results highlighted a more or less equivalent prevalence of apoliprotein E gene polymorphisms in migraineurs and in subjects suffering from ischemic cardiopathy.Further research is required to confirm the findings of the present study in a larger sample and to elucidate the role of APOE polymorphism in headache.
Our study analysed the incidence of genetic polymorphism Apoliporotein E in a sample of migraineurs and a control group of the patients with ischemic cardiopaty.
In this study 100 consecutive patients aged 18-64 years (mean age 33.7 years), suffering from migraine [1] (78 migraine without aura, 22 migraine with aura, ICHD-II criteria ) and 90 patients aged 36-74 years (mean age 46.5 years), with ischemic cardiopathy [2] were studied with Polymerase Chain Reaction (PCR) for genetic polymorphism Apoliporotein E.
ApoE: 71 patients (71%) [1] and 63 (70%) [2] had an E3/E3 genotype; 15 (15%) [1] and 14 (15,5%) [2] had a E3/E4 genotype; 6 (6%) [1] and 9 (10%) [2] had a E2/E3 genotype; 2 (2%) [1] and 4 (4.4%) [2] had a E4/E4 genotype; 3 (3%) [1] and 0 [2] had a E2/E4 genotype; 0 [1] and 0 [2] had a E2/E2 genotype.
Our results highlighted a more or less equivalent prevalence of apoliprotein E gene polymorphisms in migraineurs and in subjects suffering from ischemic cardiopathy.Further research is required to confirm the findings of the present study in a larger sample and to elucidate the role of APOE polymorphism in headache.